Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing and commercializing late-stage, risk-reward balanced cardiovascular therapies that address large unmet clinical needs. The company operates within the medical devices and cardiovascular therapeutics industries, with an emphasis on technologies designed to improve outcomes in interventional cardiology and electrophysiology. Its business model combines internal development with strategic partnerships involving large, established medical device companies to support commercialization and distribution.
The company’s primary revenue drivers are milestone payments, collaboration revenue, and long-term royalty streams tied to partnered products rather than direct large-scale product sales. Orchestra BioMed is positioned as a capital-efficient developer, leveraging partners’ global infrastructure while retaining meaningful economic participation. The company traces its origins to earlier biomedical innovation platforms and completed its current corporate formation through a merger with a special purpose acquisition company, becoming publicly listed on Nasdaq in 2023.
Business Operations
Orchestra BioMed operates through two core business programs centered on cardiovascular disease. The Virtue Sirolimus-Eluting Balloon (SEB) program targets the treatment of coronary artery disease and in-stent restenosis, utilizing a drug-coated balloon designed to deliver sirolimus to affected vessels. The BackBeat Cardiac Neuromodulation Therapy (CNT) program is focused on treating patients with hypertension who require pacemakers, using a proprietary algorithm integrated into implantable cardiac devices.
The company conducts research, clinical development, and regulatory activities primarily in the United States, while commercialization efforts are largely executed through strategic partners. Orchestra BioMed controls key intellectual property related to its technologies and relies on collaborations rather than manufacturing scale. Its most significant partnership is with Medtronic plc, which supports global development and potential commercialization of the BackBeat CNT therapy under a structured collaboration and licensing agreement.
Strategic Position & Investments
Orchestra BioMed’s strategic direction emphasizes advancing late-stage clinical assets while minimizing commercialization risk through partnerships. Growth initiatives focus on progressing pivotal clinical trials, securing regulatory approvals, and expanding indications for its core technologies. The collaboration with Medtronic plc represents a central strategic investment, providing funding, development support, and access to global distribution channels while preserving future royalty and milestone economics for Orchestra BioMed.
The company has not positioned itself as an acquirer of operating companies but instead invests heavily in internal research and development. Its portfolio is concentrated in cardiovascular medical devices, particularly interventional cardiology and electrophysiology, with an emphasis on device-based therapies that integrate with existing clinical workflows and infrastructure.
Geographic Footprint
Orchestra BioMed is headquartered in the United States, with its principal executive offices in New Hope, Pennsylvania. The company’s operational footprint is primarily U.S.-based, encompassing research, clinical trial management, regulatory affairs, and corporate administration.
International presence is largely indirect and driven by strategic partnerships. Through collaborations with global medical device companies, Orchestra BioMed’s technologies are intended for deployment across North America, Europe, and other international markets, subject to regulatory approvals. The company’s global influence is therefore tied more to partnered commercialization than to direct overseas operations.
Leadership & Governance
Orchestra BioMed is led by an executive team with experience in medical devices, cardiovascular medicine, and public company governance. The leadership philosophy emphasizes disciplined capital allocation, clinical rigor, and strategic collaboration with industry leaders to scale innovation efficiently.
Key executives include:
- David P. Hochman – Chief Executive Officer and Chairman
- Steven R. Plisek – President and Chief Operating Officer
- Darren J. Sherman – Chief Financial Officer
- Dr. Daniel D. Liberman – Chief Medical Officer
- Michael A. Jansen – Chief Technology Officer
The board of directors includes industry veterans and former senior executives from major healthcare and medical device organizations, supporting governance aligned with long-term shareholder value creation.